Skip to main content

Advertisement

Log in

Oncology's trials

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Project survival rates.
Figure 2: Target mechanisms for oncology development projects.
Figure 3: Expected growth of global oncology market.

References

  1. Fossa, S. & Skovlund, E. Selection of Patients May Limit the Generalizability of Results from Cancer Trials. Acta Oncologica. 41, 131–137 (2002).

    Article  PubMed  Google Scholar 

  2. Stadtmauer, E. et al. Conventional dose chemotherapy compared with high dose chemotherapy plusautologous hematopoietic stem cell transplantation for metastatic breast cancer. N. Engl. J. Med. 342, 1069–1076 (2000).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Related links

Related links

DATABASES

LocusLink

EGFR

VEGF

Rights and permissions

Reprints and permissions

About this article

Cite this article

Booth, B., Glassman, R. & Ma, P. Oncology's trials. Nat Rev Drug Discov 2, 609–610 (2003). https://doi.org/10.1038/nrd1158

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1158

  • Springer Nature Limited

This article is cited by

Navigation